Keck School Faculty

Gino In

Gino In

Assistant Professor of Clinical Medicine
Medicine
NOR 3440 NTT Health Sciences Campus Los Angeles

Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database Exp Biol Med (Maywood). 2020 Oct 05; 1535370220959657. . View in PubMed

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases Oncotarget. 2020 Aug 18; 11(33):3118-3128. . View in PubMed

Skin cancer and dermatoses in a majority-Hispanic population of solid organ transplant recipients J Am Acad Dermatol. 2020 Aug; 83(2):607-610. . View in PubMed

Rapidly Progressive Porocarcinoma of the Ear and Multidisciplinary Approach to Management Dermatol Surg. 2020 Mar 04. . View in PubMed

Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease Cancer Med. 2020 Feb; 9(4):1441-1450. . View in PubMed

Prevalence and correlates of adherence to skin examination among adolescent and young adult survivors of melanoma from the Project Forward Study Pediatr Blood Cancer. 2020 03; 67(3):e28090. . View in PubMed

Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma Int Ophthalmol Clin. 2020; 60(2):77-89. . View in PubMed

Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma JAAD Case Rep. 2019 Sep; 5(9):763-766. . View in PubMed

Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation BMJ Case Rep. 2019 Jun 20; 12(6). . View in PubMed

Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center Dermatol Surg. 2019 02; 45(2):254-267. . View in PubMed

Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance Nat Commun. 2019 04 12; 10(1):1693. . View in PubMed

Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma JAAD Case Rep. 2018 Nov; 4(10):1004-1006. . View in PubMed

Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature Dermatol Surg. 2018 10; 44(10):1247-1261. . View in PubMed

Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer Converg Sci Phys Oncol. 2017 Sep; 3(3). . View in PubMed

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. . View in PubMed

Skin Cancer Prevention Among Hispanics: a Review of the Literature Epidemiology. 2017. . View in PubMed

Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer Convergent Science Physical Oncology. 2017; 3(3). . View in PubMed

Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies Urol Clin North Am. 2015 Aug; 42(3):347-57. . View in PubMed

Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer Transl Cancer Res. 2015; 4(4):340-355. . View in PubMed

Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.
Powered by SC CTSI
Go to Top